Mar 18 |
Optimism around Hikma Pharmaceuticals (LON:HIK) delivering new earnings growth may be shrinking as stock declines 3.3% this past week
|
Feb 26 |
Merck's Bridion faces generic threat from drugmaker Hikma
|
Feb 21 |
Hikma hosts White House Drug Policy Director Dr. Rahul Gupta at its Columbus, Ohio manufacturing facility
|
Feb 8 |
High-dose opioid reversal spray no better than lower dose in field, US study finds
|
Feb 5 |
Hikma announces US launch of COMBOGESIC® IV
|
Feb 1 |
UPDATE 1-Ad firm Publicis, drugmaker Hikma settle US opioid cases for $500 million
|
Feb 1 |
Ad firm Publicis, drugmaker Hikma settle US opioid cases for $500 million
|
Jan 29 |
Hikma Pharmaceuticals PLC's (LON:HIK) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
|
Jan 8 |
Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa
|
Dec 25 |
Are Investors Undervaluing Hikma Pharmaceuticals PLC (LON:HIK) By 26%?
|